AstraZeneca PLC Heart Drug Faces Hurdles in Tough EU Market

April 6, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, April 6 (Reuters) - AstraZeneca's (AZN.L) big new drug hope Brilinta faces an uphill fight in Europe as its maker negotiates a series of hurdles that underscore the tough pharmaceutical landscape across the continent.

Twitter
LinkedIn
Facebook
Email
Print

Europe

AstraZeneca Pharmaceuticals LP